Abiopharma

🔍 Troendle August J. (Executive)

Company: Medpace Holdings, Inc. (MEDP)

Report Date: 2026-08-12

Detailed Transactions and Holdings:

• Sold 11,366 shares of Common Stock at $601.53 per share (Direct)
  Date: 2026-08-12 | Code: S | equity_swap_involved: false | shares_owned_after: 604,436.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 458 shares of Common Stock at $600.39 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: false | shares_owned_after: 603,978.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-12 | Code: H | nature_of_ownership: By Medpace Investors, LLC | shares_owned_after: 4,733,019.00 | Footnotes: F4

Footnotes:

• F1: The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
• F2: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.00 to $603.64. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
• F3: The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $600.345 to $600.47. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
• F4: The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.